For the quarter ending 2025-09-30, TXMD made $784,000 in revenue. $152,000 in net income. Net profit margin of 19.39%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| License revenue | 784,000 | 952,000 | 393,000 | 490,000 |
| Selling, general and administrative | - | 1,551,000 | 1,081,000 | 1,100,500 |
| General and administrative | 1,518,000 | - | - | - |
| Impairment of long-lived assets (note 4) | - | 0 | - | 2,333.333 |
| Write-off of patents and trademarks | 32,000 | 0 | 88,000 | - |
| Depreciation and amortization | 96,000 | 96,000 | 95,000 | 137,666.667 |
| Total operating expenses | 1,646,000 | 1,647,000 | 1,264,000 | 1,220,500 |
| Loss from operations | -862,000 | -695,000 | -871,000 | -730,500 |
| Interest expense and other financing costs | 3,000 | 2,000 | 2,000 | - |
| Sublease income | 534,000 | 376,000 | - | - |
| Miscellaneous income | 381,000 | 866,000 | 205,000 | 367,500 |
| Total other income, net | 912,000 | 1,240,000 | 203,000 | 367,500 |
| Income (loss) from continuing operations before income taxes | 50,000 | 545,000 | -668,000 | -363,000 |
| Income tax benefit | - | 0 | -32,000 | -7,750 |
| Income (loss) from continuing operations, net of income taxes | 50,000 | 545,000 | -636,000 | -347,500 |
| Income (loss) from discontinued operations, net of income taxes | 102,000 | 6,000 | -17,000 | 106,500 |
| Net income (loss) | 152,000 | 551,000 | -653,000 | -241,000 |
| Net income (loss) per common share, basic (in dollars per share) | 0.01 | 0.05 | -0.06 | -0.025 |
| Net income (loss) per common share, diluted (in dollars per share) | 0.01 | 0.05 | -0.06 | -0.025 |
| Weighted average common shares, basic (in shares) | 11,574,000 | 11,574,000 | 11,552,000 | -11,526,234 |
| Weighted average common shares, diluted (in shares) | 11,574,000 | 11,574,000 | 11,552,000 | -11,526,234 |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)